Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

Factors associated with recurrence and survival length following relapse in patients with neuroblastoma

(2016) Nermine O Basta et al.   BRITISH JOURNAL OF CANCER

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

(2016) Lucas Moreno et al.   PEDIATRIC BLOOD & CANCER

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

(2015) M. Merz et al.   HAEMATOLOGICA

NF-κB Regulates Caspase-4 Expression and Sensitizes Neuroblastoma Cells to Fas-Induced Apoptosis

(2015) Hai-Jie Yang et al.   PLoS One

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

(2015) M. Merz et al.   HAEMATOLOGICA

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

(2013) Susan G Kreissman et al.   LANCET ONCOLOGY

Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework

(2012) A. Doussau et al.   Contemporary Clinical Trials

The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials

(2011) Lili Zhao et al.   Clinical Trials

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium

(2009) Arzu Onar et al.   Journal of Biopharmaceutical Statistics

Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study

(2009) Lars M. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients

(2009) Alessandro Corso et al.   LEUKEMIA RESEARCH

NF-κB mediates MPP+-induced apoptotic cell death in neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1

(2009) Hai-Jie Yang et al.   NEUROCHEMISTRY INTERNATIONAL

A comparison of model choices for the continual reassessment method in phase I cancer trials

(2009) X. Paoletti et al.   STATISTICS IN MEDICINE

Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341)

(2008) Serra Kamer et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

(2008) Andrew DJ Pearson et al.   LANCET ONCOLOGY